This article is more than 5 years old. Information may no longer be current.

Piramal Healthcare announces positive results of phase III clinical trial for BST-CarGel

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Piramal Healthcare Bio-Orthopaedics, a division of Piramal Healthcare Limited, announced in a press release positive data from their phase III clinical trial of BST-CarGel at the International Cartilage Repair Society World Congress 2012.

The international, multicenter randomized clinical trial was conducted to evaluate the efficacy of BST-CarGel at 12 months for the repair of cartilage lesions and improvement in patients’ clinical symptoms compared to microfracture. According to the release, BST-CarGel treatment met its co-primary trial endpoints by achieving statistical significance over microfracture in both the degree of fill for treated lesions and the quality of the new tissue.

“The 2012 ICRS World Congress is the best venue for Piramal to announce our positive clinical findings for BST-CarGel, as the ICRS membership includes the most renowned international orthopedic surgeons and researchers in this growing clinical field,” Swati A. Piramal, PhD, director of Piramal Healthcare Limited, stated in the release. “Our symposium at ICRS represents the next step in our commercialization pathway for this exciting, new medical device.”